Compare Amylx Pharmaceuticals Inc (AMLX) vs Sony Group Corp (SONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Sony Group Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Sony Group Corp trades at $20.62 (market cap $121.92B). The key difference: Sony Group Corp is far larger — about 61.6× Amylx Pharmaceuticals Inc's market cap, and Sony Group Corp pays a 0.76% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SONY | |
|---|---|---|
Market Cap | $1.98B | $121.92B |
Sector | Health | Technology |
52-Week High | $18.70 | $30.26 |
52-Week Low | $7.64 | $19.32 |
Enterprise Value | $1.70B | $118.41B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Sony trades at $20.85, down 0.38% on the day, with a neutral technical signal. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong operating cash flow of $2.32 trillion in 2025, though net income margin remains negative at -2.62%. Key news includes Sony's plan to phase out PlayStation physical discs by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook is cautiously optimistic with 69% analyst buy ratings, but risks include execution of digital transition and projected negative net income in 2026. The stock's valuation appears reasonable with a P/E of 19.68, but investors should monitor earnings consistency and market reception to strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
